PRIMARY BILIARY CHOLANGITIS TREATMENT MARKET
Primary biliary cirrhosis, also known as primary biliary cholangitis is a chronic liver disease, which causes liver inflammation, fibrosis, and obstruction in the bile duct leading to destruction of small bile ducts within liver. Cause for primary biliary cirrhosis can be autoimmunity, infection and/or genetic predisposition. Symptoms of primary biliary cirrhosis include itching, osteoporosis, elevated serum cholesterol, and malabsorption of fat, and fat soluble vitamins, which can advance to hepatomegaly, hyperpigmentation, splenomegaly, jaundice, sicca syndrome or Kayser-Fleischer rings. Primary biliary cirrhosis develops over time and may cause the liver to stop working completely in later stages. The global primary biliary cholangitis treatment market size was valued at US$ 526.4 million in 2017, and is expected to witness a CAGR of 36.3% during the forecast period (2018 u2013 2026).
158 views • 10 slides
